

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

OMNI MEDICAL HOLDINGS INC
Form 10KSB/A
December 16, 2004

U. S. Securities and Exchange Commission
Washington, D. C. 20549

FORM 10-KSB-A1

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the fiscal year ended March 31, 2004

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File No. 000-26177

OMNI MEDICAL HOLDINGS, INC.
(Name of Small Business Issuer in its Charter)

UTAH 87-0425275
(State or Other Jurisdiction of (I.R.S. Employer I.D. No.)
incorporation or organization)

1107 Mt. Rushmore Road, Suite 2
Rapid City, South Dakota 57701

(Address of Principal Executive Offices)

Issuer's Telephone Number: (605) 718-0380

N/A
(Former Name or Former Address, if changed since last Report)

Securities Registered under Section 12(b) of the Exchange Act: None
Name of Each Exchange on Which Registered: None
Securities Registered under Section 12(g) of the Exchange Act:

\$.001 par value common stock

Check whether the Registrant (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the Registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

(1) Yes X No (2) Yes X No
--- --- --- ---

Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B is not contained in this Form, and no disclosure will be
contained, to the best of the Registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form
10-KSB or any amendment to this Form 10-KSB. []

State Registrant's revenues for its most recent fiscal year: March 31,
2004 - \$1,181,146.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Mississippi The aggregate purchase price was \$403,979, including \$150,000 paid at closing, a working capital loan of \$75,000 payable on November 30, 2003 (paid in February 2004), and \$215,279 payable on May 31, 2004 (subject to an adjustment based on actual revenues through May 2004). See Part III, Item 13, for reference to the Company's 8-K Current Report respecting this acquisition.

In early June, 2003, the Company retained the services of Windstone Capital, an investment banking firm in Phoenix, Arizona, to raise capital for additional acquisitions. A private placement offering began in early November, and management believes that the firm will be successful in raising \$800,000, the maximum amount of the proposed offering.

In early July, 2003, Mastel Precision, Inc. changed its name to Omni Medical Holdings, Inc., a Nevada corporation. On September 3, 2003, the name was again changed, this time to Omni Medical of Nevada. This was done in order to facilitate the impending merger with Piezo Instruments, Inc., the Registrant.

Effective September 5, 2003, Piezo Instruments Inc. ("Piezo") (OTCBB: PEZO) announced the closing of the acquisition of a majority of the outstanding securities of Omni Medical Holdings Inc., and then changed its name to "Omni Medical of Nevada Inc." ("Omni"). Terms of the Agreement and Plan of Reorganization (the "Reorganization Agreement") provided for Piezo to issue up to 16,000,000 post-split shares of its common stock to the shareholders of Omni for all of the outstanding common stock of Omni.

At the closing, and excluding the shares exchanged for Omni, the outstanding common stock of Piezo amounted to 2,000,000 shares, after taking into account a 1 for 14.5 reverse split and the following transactions: (1) In consideration of the closing of the Reorganization Agreement, certain principal stockholders of Piezo (i) delivered 1,466,379 post-split shares of Piezo for cancellation, which included 225,000 post-split shares of common stock underlying an option granted to one of the canceling stockholders; and (ii) waived any registration rights that had been granted to them or were applicable to any of the cancelled shares. In exchange for the cancellation of these shares and the waiver of any registration rights, Piezo issued an aggregate of 500,000 post-split newly issued shares of common stock to the canceling stockholders. (2) Piezo issued 293,104 shares of common stock to certain principal stockholders of Piezo in exchange for services to be rendered under a six month consulting agreement, resulting in consulting expense of approximately \$8,800, of which approximately \$2,900 is deferred at December 31, 2003.

As of October 31, 2003, the deadline for completing the share exchange transaction with Piezo, 81% of Omni's outstanding shares had been tendered to the Company in accordance with the instructions for exchanging shares (12,443,062 shares were issued through March 31, 2004 and an additional 474,659 shares are to be issued as of March 31, 2004). The other 19% of Omni's outstanding shares had taken no action whatsoever and continue to own a minority interest in the Company's subsidiary. Shareholders of approximately 9,222 shares exercised their rights to dissent, and the Company repurchased the shares for an aggregate of \$120.

Omni Medical also announced the addition of Lance Weaver to the Board of Directors effective October 1, 2003. Mr. Weaver is a stockholder in the Company.

Effective December 1, 2003, Omni completed an Asset Purchase Agreement with McCoy Business Services, Inc. ("McCoy"), a corporation based in Kentucky and a provider of medical transcription services. The aggregate purchase price was \$391,989 including \$156,300 payable at closing, and \$235,689 payable in

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

eight equal quarterly installments beginning on February 29, 2004. The quarterly payments are subject to an earn-out provision to be calculated based on a multiple of the amount by which revenues for each quarter are greater or less than a baseline amount. See Part III, Item 13, for reference to the Company's 8-K Current Report respecting this acquisition.

On May 10, 2004, our Board of Directors resolved to dismiss Gelfand, Hochstadt Pangburn, P.C., as our principal independent accountant and to retain Mantyla McReynolds, Certified Public Accountants, of Salt Lake City, Utah, as our new principal independent accountant, and to audit our financial statements for the fiscal year ended March 31, 2004. See Part III, Item 13, for reference to the Company's 8-K Current Report respecting this action.

Business.

Omni Medical Holdings is in the business of providing medical services to doctors, clinics and hospitals. Currently, we provide medical transcription, billing and collection services. We are actively acquiring companies in these industries as well as other medical services related areas.

Principal Products or Services and their Markets.

Omni provides medical transcription service to hospitals and healthcare facilities currently in seven states. Whenever a health care provider makes a diagnosis or provides a patient treatment, those actions must be documented. Government and insurance regulations are such that these important medical records, which affect patient health, must be in readable form. This results in the health care provider dictating the patient treatment in some form and someone else typing that dictation. Due to the obvious importance of this task, a transcriptionist must have a level of training well beyond a normal typist. This would include detailed knowledge of medical terminology and working knowledge of health and science principles in a variety of medical disciplines. Transcription has become an important and essential service in all healthcare practices. Clients are usually charged a line rate of \$0.11 - \$0.18, depending on the work involved. Transcriptionists are usually hired on a subcontract basis, work out their home and are compensated on a per line basis. Quality assurance and other management personnel are full-time employees, provide services at the corporate office and are compensated on a salary basis.

Omni also provides medical billing and collections services in the State of Mississippi. Medical billing and collections are the lifeblood of any healthcare facility. Accurate and timely collections insure an efficient practice and high standard of care.

Omni is currently operating in seven states. The market, however, can encompass the entire country made possible through the electronic transfer of data. It is the intention of Omni Medical to focus its marketing efforts on mid-size metropolitan cities throughout the United States. Its expansion and acquisition strategies will position Omni to become a nationwide provider of medical services.

Distribution Methods of the Products or Services.

The finished product (e.g., transcribed lines) is distributed digitally through electronic transmission to the client. Medical billings are either mailed or sent electronically first to the insurance companies. The patient is then billed for any difference that was not received from their insurance company. Insurance company and patient payments are remitted to a banking

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

institution lockbox designated under the doctor's name or healthcare facility. Collections activities involve following up with either the insurance companies or patient for any payment not yet received within a designated amount of time.

Status of any Publicly Announced New Product or Service.

None; not applicable.

Competitive Business Conditions.

Healthcare services (e.g., transcription, billing, collections) is a highly fragmented industry. Two of our largest competitors are Medquist, Inc. ("MEDQ") and IDX Systems Corporation ("IDXC"), both of which are large and well funded publicly traded companies, with substantially more assets and resources than Omni. The primary competition comes from the healthcare facility itself. Due to the overhead expense of providing these services internally, more healthcare facilities will be looking to outsource these duties to reduce costs.

Transcription has become an important and essential service in all healthcare practices. According to the "MTIA," (a transcription trade association), medical transcription is a fragmented \$15 billion industry, with revenues projected to approach \$25 billion over the next five years.

Medical billing and collections are the lifeblood of any healthcare facility. Accurate and timely collections ensure an efficient practice and high standard of care. Although no industry figures are available, it is known that approximately \$1.5 trillion was spent on health care in the United States last year. Assuming that half of that amount occurred at the point of care, that would be a potential billing market of \$750 billion. Health care providers that use billing services generally pay between 6-10% of the amount collected on their behalf. This would put the potential estimated revenue for billing services somewhere between \$45-75 billion, and growing at a rate of 8% annually. With the rising cost of health care and an aging population, in five years the market could well be generating over \$100 billion in annual revenue. Within the billing industry, there are generally no subcontractors, and all work from the corporate office.

According to United State Government studies, the medical industry is growing at a rate of 8% annually, with estimates as high as 12% in the coming years. The need for medical services by healthcare providers will continue to mirror that growth rate. It is widely known that an increasingly aging population, along with a country that will spare no expense for personal consumption of medical care, will contribute to this growth. Healthcare providers will also remain under pressure to reduce operating expense and expand margins. The effect is that services currently provided internally will now be more readily outsourced. The outsourcing trend allows the health care provider to focus time and resources on providing health care, giving the opportunity for growth potential to medical service providers like Omni.

Sources and Availability of Raw Materials and Names of Principal Suppliers.

None; not applicable.

Dependence on One or a Few Major Customers.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

None; not applicable.

Patents, Trademarks, Licenses, Franchises, Concessions, Royalty
Agreements or Labor Contracts.

None; not applicable.

Need for any Governmental Approval of Principal Products or Services.

Government regulations concerning the privacy of patient's health records are being phased in at this time. Known as "HIPPA," the effects of these regulations have been for all healthcare providers and vendors to upgrade both security and technology of patient records. For Omni as a vendor, it is compliant with HIPPA regulations and believes these regulations will only encourage healthcare providers to outsource more medical services.

Effect of Existing or Probable Governmental Regulations on Business.

Small Business Issuer.

The integrated disclosure system for small business issuers adopted by the Securities and Exchange Commission in Release No. 34-30968 and effective as of August 13, 1992, substantially modified the information and financial requirements of a "Small Business Issuer," defined to be an issuer that has revenues of less than \$25 million; is a U.S. or Canadian issuer; is not an investment company; and if a majority-owned subsidiary, the parent is also a small business issuer; provided, however, an entity is not a small business issuer if it has a public float (the aggregate market value of the issuer's outstanding securities held by non-affiliates) of \$25 million or more.

The Securities and Exchange Commission, state securities commissions and the North American Securities Administrators Association, Inc. ("NASAA") have expressed an interest in adopting policies that will streamline the registration process and make it easier for a small business issuer to have access to the public capital markets.

We are deemed to be a "small business issuer," and we have selected to comply with the "small business issuer" disclosure requirements of Regulation SB of the Securities and Exchange Commission.

"Penny Stock" Designation.

Our common stock is "penny stock" as defined in Rule 3a51-1 of the Securities and Exchange Commission. Penny stocks are stocks:

- * with a price of less than five dollars per share;
- * that are not traded on a "recognized" national exchange;
- * whose prices are not quoted on the NASDAQ automated quotation system; or
- * in issuers with net tangible assets less than \$2,000,000, if the issuer has been in continuous operation for at least three years, or \$5,000,000, if in continuous operation for less than three years, or with average revenues of less than \$6,000,000 for the last three years.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Section 15(g) of the Exchange Act and Rule 15g-2 of the Securities and Exchange Commission require broker/dealers dealing in penny stocks to provide potential investors with a document disclosing the risks of penny stocks and to obtain a manually signed and dated written receipt of the document before making any transaction in a penny stock for the investor's account. You are urged to obtain and read this disclosure carefully before purchasing any of our shares.

Rule 15g-9 of the Securities and Exchange Commission requires broker/dealers in penny stocks to approve the account of any investor for transactions in these stocks before selling any penny stock to that investor. This procedure requires the broker/dealer to:

- * get information about the investor's financial situation, investment experience and investment goals;
- * reasonably determine, based on that information, that transactions in penny stocks are suitable for the investor and that the investor can evaluate the risks of penny stock transactions;
- * provide the investor with a written statement setting forth the basis on which the broker/dealer made his or her determination; and
- * receive a signed and dated copy of the statement from the investor, confirming that it accurately reflects the investor's financial situation, investment experience and investment goals.

Compliance with these requirements may make it harder for our stockholders to resell their shares.

Research and Development.

None; not applicable.

Cost and Effects of Compliance with Environmental Laws.

None; not applicable.

Number of Employees.

Our Company currently employs 29 employees, of which 25 are full-time.

Item 2. Description of Property.

Omni has an interest in three parcels of real property: 1609 West Street, Montgomery, Alabama, that it is purchasing; 1867 Crane Ridge Drive, Suite #250-A, Jackson, Mississippi, and 1107 Mt. Rushmore Road, Suite 2, Rapid City, South Dakota, both of which are leased.

Item 3. Legal Proceedings.

To the knowledge of our management, no director or executive officer is party to any action in which any has an interest adverse to us, except that on October 1, 2003, certain minority shareholders of Omni notified the Company that they believe that Omni has taken actions that have diluted their interests. These minority shareholders have demanded the return of certain assets or a substantial financial settlement to be reached within 15 days.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

These minority shareholders have notified the Company of their intentions to make a filing with the American Arbitration Association pursuant to the Agreement for the Exchange of Common Stock dated April 15, 2002 if the matter is not resolved within the 15 day time frame. No such filing has been made and there have been no stated monetary damages claimed. Management believes that the issues raised by these minority shareholders is without merit and management intends to vigorously defend any action, if filed. However, it is too early to determine the ultimate outcome of the matter.

Item 4. Submission of Matters to a Vote of Security Holders.

No matter was submitted to the Company's shareholders during the last quarter of our current fiscal year.

PART II

Item 5. Market for Common Equity and Related Stockholder Matters.

Market Information.

There has never been any "established trading market" for our shares of common stock. Our common stock is presently quoted on the OTC Bulletin Board of the NASD under the symbol "ONMH" as reflected below. No assurance can be given that any market for our common stock will develop in the future or be maintained. If an "established trading market" ever develops in the future, the sale of "restricted securities" (common stock) pursuant to Rule 144 of the Securities and Exchange Commission by members of management or others may have a substantial adverse impact on any such market.

The range of high and low bid quotations for our common stock during each quarter for the last year, are shown below. Prices are inter-dealer quotations as reported by the NQB, LLC, and do not necessarily reflect transactions, retail markups, mark downs or commissions.

Stock Quotations

Quarter Ended -----	High ----	Low ---
April 1, 2003 through June 30, 2003	\$0.03	\$0.03
July 1, 2003 through August 22, 2003	\$0.03	\$0.02
August 25, 2003 through September 30, 2003*	\$1.25	\$0.02
October 1, 2003 through December 31, 2003	\$1.26	\$0.30
January 1, 2004 through March 31, 2004	\$0.78	\$0.26

*After a 1 for 14.5 reverse split.

Recent Sales of Unregistered Securities.

On November 5, 2002, pursuant to Unanimous Consent of the Company's Board of Directors, the Company resolved to issue 18,000,000 shares of the Company's "unregistered" and "restricted" \$0.001 par value common stock to Jenson Services, Inc., a Utah corporation, in consideration of \$5,000 being advanced to the Company to meet accounts payable obligations. These shares were cancelled as a condition to the closing of the Reorganization Agreement with Omni.

Holders.

As of July 9, 2004, there were 23,898,776 shares of common stock outstanding and approximately 305 stockholders of record.

Dividends.

We have not paid any cash dividends since our inception and do not anticipate or contemplate paying dividends in the foreseeable future. It is the present intention of management to utilize all available funds for the development of our business.

Securities Authorized For Issuance under Equity Compensation Plans.

We do not have any Equity Compensation Plans presently in place.

Item 6. Management's Discussion and Analysis or Plan of Operation.

"SAFE HARBOR" STATEMENT UNDER THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.

This Form 10-KSB contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Omni Medical Holdings, Inc. is referred to herein as "we" or "our". The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of the filing of this Form 10-KSB with the Securities and Exchange Commission and should not be relied upon as of any subsequent date. Except as may otherwise be required by applicable law, we do not undertake, and specifically disclaim, any obligation to update any forward-looking statements contained in this Form 10-KSB to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

RESULTS OF OPERATIONS

The year ended March 31, 2004.

During the fiscal year ended March 31, 2004, we recorded revenue of \$1,181,146, as compared to revenue of \$96,462 in the year ended March 31, 2003. This increase is principally due to our acquisition of Medical Billing Management, Inc. ("MBM") on May 30, 2003. Cost of sales also rose significantly, to \$748,710 in the current year, from \$0 in the fiscal year

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

ended March 31, 2003. Again, this increase is principally the result of our acquisition of MBM.

During the fiscal year ended March 31, 2004, we recorded general and administrative expenses of \$916,631. These expenses totaled \$245,599 in the year-ago period. This increase is primarily due to our acquisition of MBM, as well as increases in consulting services fees.

Interest expense was \$37,298 and \$11,876 for the year ended March 31, 2004, and March 31, 2003, respectively.

For the year ended March 31, 2004, we incurred a loss from continuing operations of \$521,493, as compared to a loss of \$128,729 for the year ended March 31, 2003.

CAPITAL RESOURCE REQUIREMENTS

LIQUIDITY

As of March 31, 2004, Omni's working capital deficit was \$543,818. Our cash at March 31, 2004 was \$6,140.

We currently have a commitment under an Employment Agreement with one of the former owners of McCoy through November 30, 2005, guaranteeing annual compensation of \$30,000 plus a performance based bonus. We currently lease office space under an operating lease for \$6,000 per month, which terminates July 31, 2006.

Effective October 1, 2003, Omni entered into an Employment Agreement with Arthur D. Lyons, its chief executive officer and president through December 31, 2008. The agreement provides compensation at an annual base salary of \$150,000 and increases to \$180,000 annually the first month Omni's gross revenue exceeds \$450,000 in a month. The Agreement also provides for a \$75,000 bonus to be paid as of February 1, 2004, and awards stock options based upon revenue targets. As of March 31, 2004, no stock options have been earned under the Agreement. We have been paying Mr. Lyons' salary since March, 2004. His salary for the period from October, 2003, through February, 2004, has been paid through the issuance of "unregistered" and "restricted" shares of our common stock.

During December 2003, Omni entered into a Loan Agreement and Security Agreement with Presidential Financial Corporation allowing the Company to borrow up to 80% of its accounts receivable or \$300,000, whichever is less. The loan is secured by accounts receivable and other tangible assets of Omni and accrues interest at prime plus 2%. As of March 31, 2004 \$44,956 was owed on the line of credit.

Item 7. Financial Statements.

Omni Medical Holdings, Inc.

Independent Auditors' Report
and
Consolidated Financial Statements

March 31, 2004

Omni Medical Holdings, Inc.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

TABLE OF CONTENTS

	Page
Independent Auditors' Report	1
Consolidated Balance Sheet - March 31, 2004	2-3
Consolidated Statements of Operations for the Years Ended March 31, 2004 and 2003	4
Consolidated Statements of Stockholders' Equity for the Years Ended March 31, 2004 and 2003	5
Consolidated Statements of Cash Flows for the Years Ended March 31, 2004 and 2003	6-7
Notes to Consolidated Financial Statements	8-19

Independent Auditors' Report

The Board of Directors and Shareholders
Omni Medical Holdings, Inc.

We have audited the accompanying consolidated balance sheet of Omni Medical Holdings Inc. as of March 31, 2004 and the related consolidated statements of operations, stockholders' equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Omni Medical Holdings, Inc., and subsidiaries as of March 31, 2004 and the results of operations and cash flows for the years ended March 31, 2004 and 2003, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that Omni Medical Holdings, Inc. will continue as a going concern. As discussed in Note 9 to the financial statements, the Company has accumulated losses from operations and a deficit in working capital. These issues raise substantial doubt about its ability to continue as a going concern. Management's plans in

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

regard to these matters are also described in Note 9. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

/s/ Mantyla McReynolds
Mantyla McReynolds
Salt Lake City, Utah
July 8, 2004

Omni Medical Holdings, Inc. Consolidated Balance Sheet March 31, 2004

ASSETS

Current assets:	
Cash and cash equivalents	\$ 6,140
Accounts receivable, net, including unbilled amounts of approximately \$214,926-Note 1	377,326
Employee advances	3,935
Prepaid expenses	3,834

Total current assets	391,235
Property & equipment, net-Notes 1& 4	262,434
Other assets:	
Deposits	380
Deferred financing costs-Note 11	25,000
Goodwill-Note 1	72,300
Intangible assets, net-Note 1	507,482

Total other assets	605,162

TOTAL ASSETS	\$1,258,831
	=====

See accompanying notes to financial statements
F-2

Omni Medical Holdings, Inc. Consolidated Balance Sheet [continued] March 31, 2004

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:	
Accounts payable	\$ 168,727
Accrued expenses	255,999
Line of credit- Note 6	44,956
Notes payable, current portion-Note 7	465,371

Total current liabilities	935,053
Notes payable, net of current portion-Note 7	229,532

Total long-term liabilities	229,532
Total liabilities	1,164,585

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Stockholders' equity:-Note 5

Preferred stock, no par value, 1,000,000 shares authorized, no shares issued and outstanding	-
Common stock, par value \$0.001 per share; 50,000,000 shares authorized; 15,260,187 issued and outstanding	15,260
Common stock to be issued under reorganization agreement 474,659 shares	475
Capital in excess of par value	1,973,648
Deferred compensation expense	(7,342)
Accumulated deficit	(1,887,795)

Total stockholders' equity	94,246

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$1,258,831
	=====

See accompanying notes to financial statements
F-3

Omni Medical Holdings, Inc.
Consolidated Statements of Operations
For the years ended March 31, 2004 and 2003

	2004	2003
Revenue	\$1,181,146	\$ 96,462
Cost of sales	748,710	-
	-----	-----
Gross operating profit	432,436	96,462
General and administrative expenses	916,631	245,599
	-----	-----
Income (loss) from operations	(484,195)	(149,137)
Other income (expense):		
Interest income	-	32,284
Interest expense	(37,298)	(11,876)
	-----	-----
Total other income (expense)	(37,298)	20,408
	-----	-----
Loss from continuing operations before income taxes	(521,493)	(128,729)
Provision for income taxes	-	-
	-----	-----
Loss from continuing operations	(521,493)	(128,729)
Loss from discontinued operations, net of taxes-Note 3	(33,736)	(386,361)
	-----	-----
Net loss	\$ (555,229)	\$ (515,090)
	=====	=====
Loss per share basic and diluted:		
Continuing operations	\$ (0.04)	\$ (0.01)
	=====	=====
Discontinued operations	\$ (0.01)	\$ (0.02)
	=====	=====
Net loss per share-basic and diluted	\$ (0.04)	\$ (0.03)
	=====	=====
Weighted average number of common shares outstanding-basic and diluted	14,708,706	19,805,993
	=====	=====

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

See accompanying notes to financial statements
F-4

Omni Medical Holdings, Inc.
Consolidated Statements of Stockholders' Equity
For the Years Ended March 31, 2004 and 2003

	Shares Issued	Common Stock	Common stock to be issued	Additional Paid in Capital
Balance April 1, 2002	12,305,536	\$12,306	\$ -	\$ 885,300
Restatement adjustment at merger with Piezo, September 5, 2003	6,607,352	6,607		(6,607)
Issuance of common stock in exchange for note payable	303,134	303		44,697
Sale of common stock pursuant to private placement	303,134	303		44,697
Stock transferred to employees by majority shareholder				52,500
Sale of common stock pursuant to private placements	1,024,628	1,025		498,975
Issuance of common stock in business acquisition	46,108	46		29,954
Earned compensation expense				
Issuance of common stock for services	30,355	30		14,783
Net loss for year ended March 31, 2003				
Balance, March 31, 2003	20,620,247	20,620	-	1,564,299
Disposition of subsidiary	(7,795,520)	(7,795)		31,720
Sale of common stock pursuant to private placements	92,216	92		44,908
Repurchase of dissenter's common stock	(9,222)	(9)		(111)
Acquisition of Piezo on September 5, 2003	2,000,000	1,525	475	(17,091)
Sale of common stock pursuant to stock purchase agreement	577,125	577		224,673
Sale of common stock pursuant to private placement	235,000	235		120,765
Issuance of common stock for services	15,000	15		4,485

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Earned compensation expense

Net loss for year ended
March 31, 2004

Balance, March 31, 2004 15,734,846 \$15,260 \$ 475 \$ 1,973,648

[CONTINUED]

Omni Medical Holdings, Inc.
Consolidated Statements of Stockholders' Equity
For the Years Ended March 31, 2004 and 2003

	Deferred Compen- sation Expense	Accumulated Deficit	Advance Receivable Shareholder	Total Stockholders' Equity (Deficit)
Balance April 1, 2002	\$ (67,778)	\$ (817,476)	\$ (24,708)	\$ (12,356)
Restatement adjustment at merger with Piezo , September 5, 2003				-
Issuance of common stock in exchange for note payable				45,000
Sale of common stock pursuant to private placement				45,000
Stock transferred to employees by majority shareholder				52,500
Sale of common stock pursuant to private placements				500,000
Issuance of common stock in business acquisition				30,000
Earned compensation expense	26,667			26,667
Issuance of common stock for services				14,813
Net loss for year ended March 31, 2003		(515,090)		(515,090)
Balance, March 31, 2003	(41,111)	(1,332,566)	(24,708)	186,534
Disposition of subsidiary			24,708	48,633
Sale of common stock pursuant to private placements				45,000
Repurchase of dissenter's common stock				(120)
Acquisition of Piezo on September 5, 2003	(8,793)			(23,884)
Sale of common stock pursuant to stock purchase agreement				225,250

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Sale of common stock pursuant to private placement		121,000
Issuance of common stock for services		4,500
Earned compensation expense	42,562	42,562
Net loss for year ended March 31, 2004	(555,229)	(555,229)
Balance, March 31, 2004	\$ (7,342) \$(1,887,795)	\$ - \$ 94,246

See accompanying notes to financial statements
F-5

Omni Medical Holdings, Inc.
Consolidated Statements of Cash Flows
For the years ended March 31, 2004 and 2003

	2004	2003
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss from continuing operations	\$ (521,493)	\$ (128,729)
Loss from discontinued operations	(33,736)	(386,361)
Adjustments to reconcile net loss to net cash used in continuing operations:		
Depreciation and amortization	116,680	25,937
Stock-based compensation expense	33,769	93,980
Stock issued for services	4,500	-
Changes in operating assets and liabilities, net of effect of business acquisition and disposition:		
Accounts receivable	(298,074)	9,418
Employee advances	(3,935)	-
Prepaid expenses	(3,834)	-
Inventories disposed of with subsidiary	400,888	146,807
Deposits	(380)	-
Accounts payable	(103,931)	996
Accrued expenses	225,741	(11,135)
	-----	-----
Net cash used in operating activities	(183,805)	(249,087)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property and equipment	(15,649)	(54,960)
Payment for disposition of subsidiary, net	(36,000)	-
Payments for purchase of businesses	(475,094)	(65,000)
	-----	-----
Net cash used in investing activities	(526,743)	(119,960)
CASH FLOWS FROM FINANCING ACTIVITIES		
Repurchase of dissenter's common stock	(120)	-
Deferred financing costs	(25,000)	-
Borrowings on line of credit	44,956	-
Proceeds from issuance of debt	75,000	125,000
Payments of notes payable	(27,361)	(52,334)
Proceeds from the issuance of common stock	391,250	545,000
	-----	-----
Net cash provided by		

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

financing activities	458,725	617,666
	-----	-----
NET INCREASE (DECREASE) IN CASH	(251,823)	248,619
CASH AT BEGINNING OF YEAR	257,963	9,344
	-----	-----
CASH AT END OF YEAR	\$ 6,140	\$ 257,963
	=====	=====

See accompanying notes to financial statements
F-6

Omni Medical Holdings, Inc.
Consolidated Statements of Cash Flows [continued]
For the years ended March 31, 2004 and 2003

	2004	2003
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Cash paid for interest in continuing operations	\$ 37,298	\$ 10,872
Cash paid for interest in discontinued operations	1,402	34,841
Cash paid for income taxes	-	-
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Conversion of debt to equity	\$ -	\$ 45,000
BUSINESS ACQUISITIONS:		
Fair value of assets acquired	\$ 795,968	\$ 184,761
Issuance of debt/assumption of liabilities	(320,874)	(89,761)
Common stock issued at acquisition	-	(30,000)
	-----	-----
Cash paid	\$ 475,094	\$ 65,000
	=====	=====

See accompanying notes to financial statements
F-7

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business - Omni Medical Holdings, Inc. ("Omni"), a Utah corporation, provides medical billing and transcription services to medical practitioners in Alabama, Mississippi, South Dakota and Kentucky.

Organization - The company was previously organized as Piezo Instruments, Inc. ("Piezo"), a Utah corporation. Effective September 5, 2003, Piezo and Omni Medical of Nevada, Inc., a Nevada Corporation ("Omni Nevada") executed an Agreement and Plan of Reorganization (the "Reorganization Agreement"), whereby Piezo agreed to acquire 100% of the issued and outstanding shares of common stock of Omni Nevada in exchange for up to 16,000,000 newly issued shares of common stock of Piezo, (of which 12,443,062 have been issued as of March 31, 2004 and 474,659 shares are to be issued as of March 31, 2004 for a total of 12,907,721 shares,) or approximately 86% of the post-Reorganization Agreement outstanding securities of Piezo. The transaction was accounted for as a reverse acquisition of Piezo by Omni Nevada. Shares of common stock authorized and issued have been retroactively restated to present the capital structure of Piezo. Concurrent with the merger, Piezo changed

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

its name to Omni Medical Holdings, Inc.

At the closing, and excluding the shares exchanged for Omni, the outstanding common stock of Piezo totaled 2,000,000 shares, after taking into account a 1 for 14.5 reverse split and the following transactions:

1. In consideration of the closing of the Reorganization Agreement, certain principal stockholders of Piezo (i) delivered 1,466,379 post-split shares of Piezo for cancellation, which included 225,000 post-split shares of common stock underlying an option granted to one of the canceling stockholders; and (ii) waived any registration rights that had been granted to them or were applicable to any of the cancelled shares. In exchange for the cancellation of these shares and the waiver of any registration rights, Piezo issued an aggregate of 500,000 post-split newly issued shares of common stock to the canceling stockholders.
2. Piezo issued 293,104 shares of common stock to certain principal stockholders of Piezo in exchange for services to be rendered under a six month consulting agreement, resulting in consulting expense of approximately \$8,800.

As of October 31, 2003, the deadline for completing the share exchange transaction with Piezo, approximately 81% of Omni's outstanding shares had been tendered to the Company in accordance with the instructions for exchanging shares (12,443,062 have been issued as of March 31, 2004 and 474,659 shares are to be issued as of March 31, 2004 for a total of 12,907,721 shares). The other 19% of Omni's outstanding shares had taken no action whatsoever and continue to own a minority interest in the Company's subsidiary, Omni Nevada. Shareholders of approximately 9,222 post recapitalization shares exercised their rights to dissent, and the Company repurchased the shares for \$120.

On December 31, 2003, pursuant to the unanimous consent of the board of directors for Omni Medical of Nevada and Omni Medical Holdings, Inc., Omni Medical of Nevada sold, assigned and transferred to Omni Medical Holdings, Inc all shares of the common stock of Omni Medical Services, Inc. for \$100.00.

Principles of consolidation-The accompanying consolidated financial statements include the accounts of Omni Medical Holdings, Inc., its wholly owned subsidiary, Omni Medical Services, Inc. and its majority owned subsidiary, Omni Medical of Nevada, Inc. All significant intercompany balances and transactions are eliminated.

Cash and cash equivalents- The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents.

F-8

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES[continued]

Revenue recognition- The Company recognizes revenue according to Staff Accounting Bulletin 104, Revenue Recognition in Financial Statements which clarifies U.S. generally accepted accounting principles for revenue transactions. The Company recognizes revenue from two sources, medical billing and medical transcription services. Fees for the medical billing services are primarily based on a percentage of net collections on our clients' accounts receivable. Revenue is recognized for these services when the service is performed for the client based on the

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Company's percentage of the clients estimated collections. Revenues on the medical transcription services are recognized monthly as services are performed for our clients.

Use of estimates in preparation of financial statements- The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Bad debt and allowance for doubtful accounts- The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio. The Company provides an allowance for doubtful accounts which, based upon management's evaluation of numerous factors, including economic conditions, a predictive analysis of the outcome of the current portfolio and prior credit loss experience, is deemed adequate to cover reasonably expected losses inherent in outstanding receivables. The allowance at March 31, 2004 is \$32,239.

Concentrations of credit risk-The Company grants credit to its customers, generally without collateral. At March 31, 2004, two customers accounted for 42% of accounts receivable. During the years ended March 31, 2004 two customers accounted for 35% of sales, and during the year ended March 31, 2003 no one customer accounted for 10% or more of sales.

Property and equipment- Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to expense as incurred. The following is a summary of the estimated useful lives and depreciation methods used in computing depreciation expense:

Asset	Depreciation Method	Estimated useful life
Computer Equipment	Straight-line	3 years
Office Equipment	Straight-line	5 years
Furniture & Fixtures	Straight-line	7 years
Equipment - Manufacturing	Straight-line	7 years
Building & Land - Alabama	Straight-line	25 years

F-9

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES[continued]

Goodwill and intangible assets-The Company adopted Statement of Financial Accounting Standards ("SFAS") No. 142 "Goodwill and Other Intangible Assets". SFAS No. 142 addresses the accounting and reporting for acquired goodwill and other intangible assets. The Company's goodwill consists \$36,000 applicable the A&V medical transcription acquisition in July 2002 and \$36,300 applicable to the Medical Billing Management purchase in May 2003. The Company continually tests goodwill for impairment and recognizes a loss when the carrying value exceeds the fair value. The Company has recorded no impairment charges for the years ended March 31, 2004 and 2003. The intangible asset consists of customer lists acquired in the acquisitions of A&V, Medical Billing Management

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

and McCoy Business Services, Inc. as well as a trade name and non-compete agreements acquired in the McCoy acquisition. The intangible assets are being amortized over their useful life of between 2 and 5 years. Amortization expense for the years ended March 31, 2004 and 2003 were approximately \$80,100 and \$4,300, respectively.

Amortization expense for the next five years is expected to be as follows:

Year ended	
3/31/2005	\$148,390
3/31/2006	131,723
3/31/2007	98,392
3/31/2008	94,086
3/31/2009	34,891

Income taxes- The Company complies with the provisions of Statement of Financial Accounting Standards No. 109 [the Statement], "Accounting for Income Taxes." The Statement requires an asset and liability approach for financial accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and tax basis of the Company's assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled.

Net Loss Per Common share-In accordance with Statement of Financial Accounting Standards No. 128, "Earnings Per Share," basic loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share is computed using weighted average number of common shares plus dilutive common share equivalents outstanding during the period using the treasury stock method. During the years ended March 31, 2004 and 2003 there were no common share equivalents outstanding.

Stock based compensation-SFAS No. 123, "Accounting for Stock-Based Compensation" allows companies to choose whether to account for employee stock-based compensation on a fair-value method, or to account for such compensation under the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB 25"). The Company has chosen to account for stock-based compensation using APB 25. At March 31, 2004, the Company had no stock option plans.

F-10

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES[continued]

Fair value of financial instruments- The carrying amounts of the Company's cash and cash equivalents, accounts receivable and accounts payable approximate fair values due to the short maturities of these instruments. The carrying value of the Company's short-term borrowings approximates fair value based on the Company's current incremental borrowing rate for similar types of borrowing arrangements. The fair values of the company's receivables and payables to related parties are not practicable to estimate due to the related party nature of the underlying transactions and indefinite payments terms.

Derivative transactions- During the year ended March 31, 2003, the

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Company utilized certain short-term derivative instruments, options and puts of marketable equity securities, for trading purposes. The Company accounted for these transactions at fair value, based on market quotes and cash settlements. These transactions exposed the Company to certain market and credit risks related to the underlying investment and the counter-party, respectively. Included in interest income for the year ended March 31, 2003 is approximately \$30,000 of gains from these transactions. The Company had no such transaction during the year ended March 31, 2004 and held no derivative instruments at March 31, 2004 and 2003.

Recent Accounting pronouncements- In June 2002, SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, was issued. SFAS No. 146 requires recording costs associated with exit or disposal activities at their fair values when a liability has been incurred. Under previous guidance, certain exit costs were accrued upon management's commitment to an exit plan, which is generally before a liability has been incurred. The Company adopted SFAS No. 146 in September of 2003. The adoption of SFAS No. 146 did not materially impact the Company's consolidated results of operations, financial position, or cash flow.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure. SFAS No. 148 amends SFAS No. 123 to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The provisions of SFAS No. 148 are effective for financial statements for fiscal years and interim periods ending after December 15, 2002. The disclosure provisions of SFAS No. 148 have been adopted by the Company (see Stock-Based Compensation above).

SFAS No. 150, Accounting for Certain Financial Instruments with Characteristics of both Liability and Equity ("SFAS No. 150") was issued in May 2003. SFAS No. 150 establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liability and equity in its statement of financial position. SFAS No. 150 became effective for the Company for new or modified financial instruments beginning June 1, 2003, and for existing instruments beginning June 28, 2003. The adoption of SFAS No. 150 did not have a material impact on the Company's Consolidated Financial Statements.

F-11

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES[continued]

In November 2002, the Financial Accounting Standards Board ("FASB") issued Financial Accounting Standards Board Interpretation No. ("FIN") 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, which requires the guarantor to recognize as a liability the fair value of the obligation at the inception of the guarantee. The disclosure requirements in FIN 45 are effective for financial statements of interim or annual periods ending after December 15, 2002. Management believes

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

the Company has no guarantees that are required to be disclosed in the financial statements. The recognition provisions are to be applied on a prospective basis to guarantees issued after December 31, 2002. The adoption of the recognition provisions of FIN 45 did not have a material impact on the Company's financial statements.

In January 2003, the FASB issued FIN No. 46, Consolidation of Variable Interest Entities, an interpretation of Accounting Research Bulletin ("ARB") No. 51. FIN No. 46, as revised in December 2003, addresses consolidation by business enterprises of variable interest entities. FIN No. 46 applies immediately to variable interest entities created after January 31, 2003, and to variable interest entities in which an enterprise obtains an interest after that date. FIN No. 46 applies in the first year or interim period ending after December 15, 2003, to variable interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. The adoption of FIN No. 46 did not have a material impact on the Company's financial statements.

Note 2 BUSINESS ACQUISITIONS

Effective December 1, 2003, Omni, through its wholly-owned subsidiary, Omni Medical Services, Inc., ("OMS"), completed an asset purchase agreement with McCoy Business Services, Inc. ("McCoy"), a corporation based in Kentucky and a provider of medical transcription services. The aggregate purchase price was \$391,989, including \$156,300 payable at closing, and \$235,689 payable in eight equal quarterly installments of \$30,000 beginning on February 29, 2004. The quarterly payments are subject to an earn-out provision to be calculated based on a multiple of the amount by which revenues for each quarter are greater or less than a baseline amount. The adjustments will be recorded as an adjustment to the acquisition cost of McCoy. The first quarterly payment paid on March 31, 2004 was reduced by \$1,878, the second quarterly payment was reduced by \$2,433.

The following table summarizes the estimated fair values of the assets acquired as of December 1, 2003, the date of acquisition. The allocation of the purchase price is subject to refinement.

Furniture and equipment	\$ 60,000
Intangible asset - customer list	135,689
Intangible asset - covenant not to compete	100,000
Intangible asset - trade name	60,000
Goodwill	36,300

Net assets acquired	\$391,989
	=====

F-12

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 2 BUSINESS ACQUISITIONS [continued]

Effective May 30, 2003, Omni, through OMS, completed an asset purchase agreement with Medical Billing Management, Inc. ("MBM"), a corporation based in Mississippi and a provider of medical billing and collection services to medical practitioners. The aggregate purchase price was \$403,979, including \$150,000 paid at closing, \$75,000 payable on November 30, 2003 (paid in February 2004) and \$215,279 payable on May

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

31, 2004 (unpaid as of July 5, 2004). The May 31, 2004 payable was subject to an adjustment which was calculated based on a multiple of the amount by which revenues for the year ending May 31, 2004 was less than a baseline amount. The adjustment reduced the acquisition cost of MBM by \$46,021. The following table summarizes the estimated fair values of the assets acquired as of May 30, 2003, the date of acquisition. The aggregate purchase price was discounted by \$20,000 to impute interest on the non-interest bearing debt payable on November 30, 2003 and May 31, 2004. This discount has resulted in a \$20,000 decrease to the amount included in intangible assets from the Company's initial allocation of the purchase price.

Accounts receivable, net	\$ 62,000
Furniture and equipment	78,000
Intangible asset-customer list	263,979

Net assets acquired	\$403,979

Effective July 10, 2002, Omni entered into an asset purchase agreement with A&V Digital Transcription Services ("A&V"), a general partnership and provider of medical transcription services based in Alabama. On September 4, 2002, Omni formed Omni Medical Services, Inc., (formerly Mastel Precision Health Information Services, Inc. and a wholly-owned subsidiary of Omni) to operate the transcription services business acquired from A&V.

The aggregate purchase price was \$95,000, including \$65,000 in cash, assumption of liabilities of \$90,000 and common stock valued at \$30,000.

The following table summarizes the estimated fair values of the assets acquired and the liabilities assumed at July 10, 2002, the date of acquisition.

Current assets	\$ 8,000
Property, plant and equipment	109,000
Intangible asset-customer list	32,000
Goodwill	36,000

Total assets acquired	185,000
Current liabilities	(19,000)
Long-term debt	(71,000)

Total liabilities assumed	(90,000)

Net assets acquired	\$ 95,000
	=====

F-13

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 2 BUSINESS ACQUISITIONS [continued]

The McCoy, MBM and A&V acquisitions were accounted for as purchases and their results of operations are included in the Company's financial statements from the dates of acquisition. Goodwill arising on the acquisition of A&V and McCoy is expected to be fully deductible for tax purposes. Intangible assets (customer lists and trade names) acquired from McCoy, MBM and A&V are expected to be amortized over 5 years and

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

the covenant not to compete acquired from McCoy is to be amortized over 2 years.

Note 3 DISCONTINUED OPERATIONS

Through May 2, 2003, Omni also produced handheld surgical instruments used by ophthalmic surgeons in refractive, corneal and LASIK surgeries and was also a developer of technology to ophthalmic surgeons, specifically within the domain of anterior segment cataract extraction, and foldable intra ocular lens placement as well as keratorefractive procedures such as LASIK. Omni operated its surgical instruments business through its wholly-owned subsidiary, Mastel Precision Surgical Instruments, Inc ("MPSI") out of its facility in Rapid City, South Dakota.

Effective May 2003, Omni entered into an agreement with one of its officers and shareholders whereby Omni agreed to exchange 100% of the common stock of MPSI and \$36,000 cash for all shares of common stock of Omni owned individually or jointly by the officer and his wife. As of April 30, 2003, the assets of MPSI had a carrying value of approximately \$442,000 (primarily accounts receivable of approximately \$53,000, inventories of approximately \$387,000 and property and equipment of approximately \$30,000) and MPSI's obligations and liabilities had a carrying value of approximately \$527,000 (primarily accounts payable of approximately \$226,000 and debt of approximately \$286,000). Due to the related party nature of the transaction, no gain was recognized and shareholders equity was increased by \$49,000. The results of operations from MPSI have been retroactively restated as discontinued operations.

The following proforma financial information presents results as if the MBM and McCoy acquisitions had occurred at the beginning of the years ended March 31, 2004 and 2003:

	2004	2003
Revenues	\$1,962,908	\$2,071,285
Net loss	(484,186)	(344,277)
Basic and diluted loss per share	\$ (0.03)	\$ (0.02)

F-14

Omni Medical Holdings, Inc.
Notes to Consolidated Financial Statements
March 31, 2004

Note 4 PROPERTY AND EQUIPMENT

The major categories of property and equipment are as follows:

	3/31/2004
Computer Equipment	\$ 96,349
Office Equipment	37,525
Furniture & Fixtures	45,286
Equipment - Manufacturing	45,050
Building & Land - Alabama	85,000
Accumulated depreciation	(46,776)

Net property and equipment	262,434
	=====

Depreciation expense was \$36,514 in 2004, and \$21,633 in 2003.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Note 5 STOCKHOLDERS' EQUITY

During the year ended March 31, 2004, 327,216 shares of common stock of the Company were issued in private placements at prices ranging from \$0.50 to \$0.75 per share. The sale of 200,000 shares at \$0.50 per share was with the wife of the Company's chief executive officer and president.

In December 2003, the Company entered into a Stock Escrow Agreement with an unrelated third party through which the Company issued 577,125 shares of restricted common stock to offshore investors pursuant to Regulation S, promulgated under the Securities Act of 1933. Pursuant to the agreement the escrow agent remitted 40 percent (40%) of the offer price or, \$225,250 to the Company.

In March 2004, the Company issued 15,000 shares of restricted common stock to an individual as an exit fee related to a possible acquisition of the individuals company. Management has estimated the fair market value of the exit fee as \$4,500, which has been recorded as an expense in the accompanying financial statements.

During the year ended March 31, 2003 1,327,762 post re-organization shares of common stock were issued in private placements at prices ranging from \$0.14 to \$0.49 per share; 303,134 post re-organization shares of common stock were issued in exchange for a note payable to an officer of the Company in the amount of \$45,000 and 46,108 post re-organization shares of common stock valued at \$30,000 were issued in connection with the Company's acquisition of the assets of A&V. During the year ended March 31, 2003, the Company's founding shareholder awarded 230,100 of his shares of the Company's common stock to Company employees. The Company has accounted for this award as a capital contribution by the founding shareholder resulting in compensation expense and an increase in additional paid-in capital of \$52,500. Also during the year ended March 31, 2003, the Company reserved 130,000 shares of common stock for issuance to employees as compensation. Certain employees and directors were awarded 30,355 post re-organization shares of common stock valued at \$0.49 per share resulting in compensation expense of \$14,813.

F-15

Omnimedical Holdings, Inc.
Notes to Financial Statements
March 31, 2004

Note 6 LINE OF CREDIT

On December 19, 2003 the Company entered into a loan agreement and security agreement with Presidential Financial Corporation allowing the Company to borrow up to 80% of its accounts receivable or \$300,000 whichever is less. The loan is secured by accounts receivable and other tangible assets of the Company and accrues interest at prime plus 2%. As of March 31, 2004, the Company owed \$44,956 on the line of credit.

Note 7 LONG-TERM DEBT

The following is a summary of the Company's indebtedness as of March 31, 2004:

Note payable, interest at 5%, payable in a lump sum payment,
originally due, May 2004, collateralized by the assets of MBM \$315,906

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Note payable, interest at 5%, payable in quarterly payments of \$30,000, due November 2005, collateralized by the assets of McCoy	207,867
Note payable, interest at 8%, payable in monthly installments of \$1,956, due July 2009 collateralized by all of the assets of the company	101,998
Note payable, interest at 7.9%, payable in monthly installments of \$590, due July 2016, collateralized by land and building	56,115
Note payable, related party, interest at 5%, payable in monthly installments of \$375, due September 2004	12,130
Note payable, interest at 3.2%, payable in monthly installments of \$905, due May 2004	887
Total	\$ 694,903

Future minimum note payments as of March 31, 2004, are approximately as follows:

Year Ending March 31:	Amount
2005	\$465,371
2006	109,937
2007	21,611
2008	23,426
Thereafter	74,558
	\$694,903

F-16

Omni Medical Holdings, Inc.
Notes to Financial Statements
March 31, 2004

Note 8 LEASES

The following is a schedule by years of future minimum lease payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of March 31, 2004:

Year ended	Total
March 31, 2005	\$ 100,952
March 31, 2006	90,314
March 31, 2007	24,475
Thereafter	-
	\$ 215,741

Note 9 INCOME TAXES

Below is a summary of deferred tax asset calculations on net operating loss carry forward amounts. Loss carry forward amounts expire through 2023. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax asset will not be realized.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Description	NOL Balance	Tax	Rate
Federal Income Tax	\$1,877,795	\$638,450	34%
Valuation allowance		(638,450)	

Deferred tax asset 3/31/2004		\$ 0	
		=====	

Note 10 GOING CONCERN

The Company's financial statements for the years ended March 31, 2004 and 2003 show incurred net losses of \$555,229, and \$515,090, respectively, and has a working capital deficiency of \$543,818, as of March 31, 2004, raising substantial doubt about the company's ability to continue as a going concern. Management's plans to address concerns raised by this issue include:

- a. The disposition of MPSI will allow the Company to concentrate on its medical billing and transcription operations, which management believes can be operated more profitably than MPSI. MPSI's operating losses for the years ended March 31, 2004 and 2003 were approximately \$33,700 and \$386,300, respectively.
- b. Management expects that cash flows will increase as a result of the Company's disposition of MPSI and it's acquisition of transcription and medical billing businesses.
- c. During December 2003, Omni entered into a loan agreement and security agreement with Presidential Financial Corporation allowing the Company to borrow up to 80% of its accounts receivable or \$300,000 whichever is less. The loan is secured by accounts receivable and other tangible assets of OMS and accrues interest at prime plus 2%.

F-17

Omni Medical Holdings, Inc.
Notes to Financial Statements
March 31, 2004

Note 10 GOING CONCERN [continued]

- d. The Company is currently pursuing additional sources of liquidity in the form of commercial credit or additional sales of the Company's equity securities to fund a combination of short-term working capital requirements and growth

There is no assurance that these or any efforts will be successful. However, management believes that these measures will enable the Company to have adequate funds to support operations for the next twelve months.

Note 11 RELATED PARTY TRANSACTIONS

During the year ended March 31, 2003 the Company transferred inventory with a carrying value of approximately \$20,000 to an officer and shareholder of the Company in exchange for a receivable. The shareholder used the inventory for promotional and other sales purposes on behalf of the Company. The Company entered into an agreement with the officer and shareholder whereby the receivable was to be settled in exchange for

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

32,944 shares of treasury stock, which management believes is the fair value of the stock. Accordingly, the amounts receivable from the shareholder have been shown as a reduction of stockholders equity at March 31, 2003. This agreement was terminated in connection with the disposition of MPSI in May 2003, and the receivable was acquired by the shareholder.

Note 12 COMMITMENTS AND CONTINGENCIES

In 2003, the Company retained the services of an investment banking firm to raise capital for future acquisitions. Through March 31, 2004 the Company has paid \$25,000 in deferred financing costs which will be offset against future equity proceeds.

In conjunction with the MBM acquisition, Omni entered into an employment agreement with one of the MBM's former owners, guaranteeing employment with Omni through May 30, 2004 at an annual salary of \$50,000 plus a performance based bonus.

In conjunction with the McCoy acquisition, Omni entered into an employment agreement with one of the McCoy's former owners, guaranteeing employment with Omni through November 30, 2005 at an annual salary of \$30,000 plus performance based bonuses and benefits.

Omni entered into an employment agreement with its chief executive officer and president commencing October 1, 2003 through December 31, 2008. The agreement provides compensation at an annual base salary of \$150,000 and increases to \$180,000 annually the first month Omni's gross revenue exceeds \$450,000 in a month. The agreement also provided for a \$75,000 bonus to be paid on February 1, 2004 and awards stock options based upon achieving revenue targets. As of March 31, 2004, no stock options have been earned under the agreement. The \$75,000 bonus has been accrued in these financial statements.

On October 1, 2003, certain minority shareholders of Omni notified the Company that they believe that

F-18

Omni Medical Holdings, Inc.
Notes to Financial Statements
March 31, 2004

Note 12 COMMITMENTS AND CONTINGENCIES [continued]

Omni has taken actions that have diluted their interests. These minority shareholders have demanded the return of certain assets or a substantial financial settlement to be reached within 15 days. These minority shareholders have notified the Company of their intentions to make a filing with the American Arbitration Association pursuant to the Agreement for the Exchange of Common Stock dated April 15, 2002 if the matter is not resolved within the 15 day time frame. No such filing has been made and there have been no stated monetary damages claimed. Management believes that the issues raised by these minority shareholders is without merit and management intends to vigorously defend any action, if filed. However, it is too early to determine the ultimate outcome of the matter.

Note 13 SUBSEQUENT EVENTS

On July 6, 2004 the Company announced it has reached agreement to acquire a medical service provider based in the midwest. Closing is

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

scheduled for July 15, 2004.

On June 29, 2004 the Company retained the services of Andrew & Associates, Inc. as its Investor Relations and Public Relations consulting firm.

During April, May and June 2004 , 8,276,239 shares of common stock of the Company were issued in private placements at prices ranging from \$0.32 to \$0.40 per share.

F-19

Item 8. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

On May 10, 2004, our Board of Directors resolved to dismiss Gelfand, Hochstadt Pangburn, P.C., as our principal independent accountant and to retain Mantyla McReynolds, Certified Public Accountants, of Salt Lake City, Utah, as our new principal independent accountant, and to audit our financial statements for the fiscal year ended March 31, 2004. See Item 13 of this Report.

Item 8(a). Controls and Procedures.

As of the end of the 90 day period at the end of this Annual Report, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information required to be included in our periodic reports that are filed with the Securities and Exchange Commission. It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. In addition, we reviewed our internal controls, and there have been no significant changes in our internal controls or in other factors that could significantly affect those controls subsequent to the date of their last evaluation.

PART III

Item 9. Directors, Executive Officers, Promoters and Control Persons; Compliance with Section 16(a) of the Exchange Act.

Identification of Directors and Executive Officers.

The following table sets forth the name, address, age and position of each officer and director of the Company:

Name	Age	Position
Arthur D. Lyons	45	President, CEO, and Director
John Globoker	30	Corporate Vice President, Secretary

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

and Director

Lance Weaver

44

Director

Term of Office.

Directors are elected by our stockholders to serve until the next annual meeting of our stockholders or until their successors have been elected and have duly qualified. Officers are appointed to serve until the annual meeting of our Board of Directors following the next annual meeting of our stockholders and until their successors have been elected and have qualified.

The following is a summary of the business experience of each of our current directors and executive officers:

Arthur D. Lyons. Since 1980, Mr. Lyons has held positions with Merrill Lynch, E.F. Hutton, Prudential Securities and PaineWebber as investment representative, pension consultant, trader and portfolio manager. In 1999, Mr. Lyons formed LHM Trading, an investment firm, and in 2000, founded Interstate Advisors, Inc., a registered investment advisor. Mr. Lyons' broad financial experience has provided him with a solid background in the financial and investment fields. He holds a B.A. Degree in sociology with a minor in accounting from Samford University in Birmingham, Alabama, in 1979.

John L. Globoker. Mr. Globoker was appointed Corporate Vice President and Secretary October, 1, 2003. He graduated from the University of Northern Colorado in Greeley, Colorado and earned his MBA from National American University in 2002. John has extensive marketing experience in the areas of human resources, finance and marketing primarily through his association with the Nash Finch Co. Mr. Globoker joined the Company in mid 2003, and was promoted to senior management shortly thereafter.

Lance Weaver. Director, graduated in 1982 from the South Dakota School of Mines and Technology with a degree in Mechanical Engineering. Over the past twenty years, he has owned and operated several businesses. Currently he is Vice President and shareholder in Lloyd's, Inc., an international company, based in Rapid City, South Dakota, that engineers and manufactures inspection and security robots and cameras.

Family Relationships.

There are no family relationships between Mr. Lyons, Mr. Globoker and Mr. Weaver.

Involvement in Certain Legal Proceedings.

During the past five years, none of our present or former directors, executive officers or persons nominated to become directors or executive officers:

(1) Filed a petition under the federal bankruptcy laws or any state insolvency law, nor had a receiver, fiscal agent or similar officer appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

(2) Was convicted in a criminal proceeding or named subject of a pending criminal proceeding (excluding traffic violations and other minor

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

offenses);

(3) Was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him or her from or otherwise limiting his involvement in any type of business, securities or banking activities;

(4) Was found by a court of competent jurisdiction in a civil action, by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any federal or state securities law, and the judgment in such civil action or finding by the Securities and Exchange Commission has not been subsequently reversed, suspended, or vacated.

Compliance with Section 16(a) of the Exchange Act.

We believe all forms required to be filed under Section 16 of the Exchange Act for all of the Company's directors and executive officers have been timely filed.

Audit Committee.

We have not adopted an audit committee as of the date of this Report. We will disclose when and if we do adopt an audit committee in the future.

Code of Ethics.

We have adopted a Code of Ethics and it is attached as Exhibit 14 to this Report. See Item 13 of this Report.

Item 10. Executive Compensation.

Cash Compensation.

The following table shows the aggregate compensation that we have paid to directors and executive officers for services rendered during the periods indicated:

SUMMARY COMPENSATION TABLE

Long Term Compensation

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)
Name and Principal Position	Year or Period Ended	Salary (\$)	Bonus (\$)	Other Annual Compensation	Restricted Stock	Securities-Underlying Options	LTIP Pay-outs	All Other Compensation

Arthur D.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

Lyons	3/31/04	0	0	0	0	0	0	0
President, CEO, Director	6/30/03	6000*	0	0	0	17777*	0	2200*
Charles D. Arbeiter COO, Treas., Director	3/31/04	0	0	0	0	0	0	0
	6/30/03	0	0	0	0	8889*	0	0
John Globoker Corp. V.P., Secretary, Director	3/31/04	16615	0	0	0	0	0	0
Lance Weaver director	3/31/04	0	0	0	0	0	0	0

We do not have any stock option, bonus, profit sharing, pension or similar plan; however, we may adopt such a plan in the future to attract and/or retain members of management or key employees.

Compensation of Directors

We do not compensate our Directors.

Employment Agreements

In conjunction with the MBM acquisition, Omni entered into an employment agreement with one of the MBM's former owners, guaranteeing employment with Omni through May 30, 2004 at an annual salary of \$50,000 plus a performance based bonus.

In conjunction with the McCoy acquisition, Omni entered into an employment agreement with one of the McCoy's former owners, guaranteeing employment with Omni through November 30, 2005 at an annual salary of \$30,000 plus performance based bonuses and benefits.

Omni entered into an employment agreement with its chief executive officer and president commencing October 1, 2003 through December 31, 2008. The agreement provides compensation at an annual base salary of \$150,000 and increases to \$180,000 annually the first month Omni's gross revenue exceeds \$450,000 in a month. The agreement also provided for a \$75,000 bonus to be paid as on February 1, 2004 and awards stock options based upon achieving revenue targets. As of March 31, 2004, no stock options have been earned under the agreement. The \$75,000 bonus has been accrued in these financial statements.

Item 11. Security Ownership of Certain Beneficial Owners and Management.

The following table sets forth information concerning the beneficial ownership of Onmi common stock as of July 9, 2004, by each director and executive officer, all directors and officers as a group, and each person known to beneficially own 5% or more of its outstanding common stock.

Name and Address of Beneficial Owner	Shares Owned(1)	Percentage Owned(1)
Arthur D. Lyons	1,668,937	7.0%

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

2319 Huntington Place
Rapid City, SD 57702

John L. Globoker	-0-	-0-
Lance Weaver and Cindy Weaver 3921 Mary Drive Rapid City, SD 57702	114,234	(3)
Charles D. Arbeiter 4311 S. Glenview Place Rapid City, SD 57702	1,835,852	7.7%
Langley Park Investments One Great Cumberland Place London, UK W1H7AL	3,720,930	15.6%
Al Rieman 216 N. Berry Pine Road Rapid City, SD 57702	2,503,301	10.5%
LHM Trading (2) 1107 Mt. Rushmore Road #2 Rapid City, SD 57701	3,045,721	12.7%
Warren Shy P. O. Box 1301 Spearfish, SD 57783	1,269,265	5.3%
Strategic Resources LLC One Great Cumberland Place London, UK W1H 7AL	3,700,000	15.5%
Totals:	17,744,006	74.2%

(1) Based upon 23,898,776 outstanding shares.

(2) LHM Trading is controlled by Arthur D. Lyons, the President, CEO, Secretary and a Director of Omni.

(3) Less than 1%.

Changes in Control.

To our knowledge, there are no present arrangements or pledges of our securities that may result in a change in control of our company.

Item 12. Certain Relationships and Related Transactions.

Transactions with Management and Others.

During the year ended March 31, 2003, Omni transferred inventory with a carrying value of approximately \$20,000, to an officer and shareholder of Omni in exchange for a receivable. The shareholder used the inventory for promotional and other sales purposes on behalf of Omni. Omni entered into an agreement with the officer and shareholder whereby the receivable was settled in exchange for 32,944 shares of treasury stock, which management believes is the fair value of the stock. Accordingly, the amounts receivable from the shareholder to Omni have been shown as a reduction of stockholders equity at

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

March 31, 2003. This agreement was terminated in connection with the disposition of MPSI in May 2003, and the receivable was acquired by the shareholder.

Transactions with Promoters.

Except as outlined under the caption "Transactions with Management," during the past two years, there have been no material transactions, series of similar transactions or currently proposed transactions, to which our company or any of our subsidiaries was or is to be a party, in which the amount involved exceeded \$60,000 and in which any director or executive officer, or any security holder who is known to us to own of record or beneficially more than five percent of our common stock, or any member of the immediate family of any of the foregoing persons, or any promoter or founder had a material interest.

Item 13. Exhibits and Reports on Form 8-K.

Reports on Form 8-K.

8-K Current Report dated December 1, 2003 and filed March 2, 2004, regarding an Asset Purchase Agreement with McCoy Business Services.*

8-K Current Report dated May 30, 2003 and filed May 10, 2004, regarding an Asset Purchase Agreement with Medical Billing Management.*

8-K Current Report dated May 10, 2004 and filed May 13, 2004, regarding the change in accountants.*

Exhibits*

(i)

Where Incorporated
in this Report

None.

(ii)

Exhibit Number	Description*
14	Code of Ethics**
21	Subsidiaries of the Company**
31	302 Certification of Arthur D. Lyons
32	906 Certification

* Summaries of all exhibits contained within this Report are modified in their entirety by reference to these Exhibits.

** These documents and related exhibits have been previously filed with the Securities and Exchange Commission and are incorporated herein by reference.

Edgar Filing: OMNI MEDICAL HOLDINGS INC - Form 10KSB/A

ITEM 15. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following is a summary of the fees billed to Omni by its principal accountants during the fiscal years ended March 31, 2004, and March 31, 2003:

Fee category -----	2004 ----	2003 ----
Audit fees	\$17,000	\$33,000
Audit-related fees	\$18,000	\$ 0
Tax fees	\$ 0	\$ 0
All other fees	\$ 0	\$ 0
Total fees	\$35,000	\$33,000

Audit fees. Consists of fees for professional services rendered by our principal accountants for the audit of Omni's annual financial statements and the review of financial statements included in Omni's Forms 10-QSB or services that are normally provided by our principal accountants in connection with statutory and regulatory filings or engagements.

Audit-related fees. Consists of fees for assurance and related services by our principal accountants that are reasonably related to the performance of the audit or review of Omni's financial statements and are not reported under "Audit fees."

Tax fees. Consists of fees for professional services rendered by our principal accountants for tax compliance, tax advice and tax planning.

All other fees. Consists of fees for products and services provided by our principal accountants, other than the services reported under "Audit fees," "Audit-related fees" and "Tax fees" above. The fees disclosed in this category include due diligence, preparation of pro forma financial statements as a discussion piece for a Board member, and preparation of letters in connection with the filing of Current Reports on Form 8-K.

SIGNATURES

In accordance with the requirements of the Act, the Registrant caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

OMNI MEDICAL HOLDINGS, INC.

Date: 12/15/04

/s/ Arthur D. Lyons

Arthur D. Lyons, President,
Treasurer and Director

Date: 12/15/04

/s/ John Globoker

John Globoker, Vice President,
Secretary and Director